Michelle K York1, Deepak K Gupta2, Cassandra F Reynolds1, Eric Farber-Eger1, Quinn S Wells1, Katherine N Bachmann3, Meng Xu4, Frank E Harrell4, Thomas J Wang1. 1. Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address: d.gupta@vanderbilt.edu. 3. Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Endocrinology, Vanderbilt University School of Medicine, Nashville, Tennessee; Faculty Research Scholars Program, Vanderbilt University School of Medicine, Nashville, Tennessee. 4. Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Abstract
BACKGROUND: Circulating B-type natriuretic peptide (BNP) concentrations strongly predict mortality in patients with heart failure (HF). Both cardiac and extracardiac stimuli influence BNP levels, suggesting that BNP might have similar prognostic value in patients without HF. OBJECTIVES: The aim of this study was to compare the prognostic value of BNP between patients with and those without HF. METHODS: Using the Vanderbilt University Medical Center electronic health record, 30,487 patients (median age 63 years, 50% men, 17% black, 38% with HF) who had a first plasma BNP measurement between 2002 and 2013, with follow-up through 2015, were studied. The risk for death according to BNP level was quantified using multivariate Cox proportional hazards models. RESULTS: BNP levels were lower in patients without HF (median 89 pg/ml; interquartile range: 34 to 238 pg/ml) compared with those with HF (median 388 pg/ml; interquartile range: 150 to 940 pg/ml) (p < 0.0001). Over 90,898 person-years of follow-up, 5,903 patients without HF (31%) and 6,181 patients with HF (53%) died. In multivariate models including demographic and clinical characteristics, BNP and age were the strongest predictors of death in both patients with and those without HF. In acute care settings and even among outpatients with modestly elevated BNP, the risk for death according to BNP was similar between patients with and those without HF. For instance, a BNP level of 400 pg/ml was associated with a 3-year risk for death of 21% (95% confidence interval: 20% to 23%) and 19% (95% confidence interval: 17% to 20%) in patients with and those without HF, respectively. CONCLUSIONS: Among patients without HF, plasma BNP level is a stronger predictor of death than traditional risk factors. The risk for death associated with any given BNP level is similar between patients with and those without HF, particularly in the acute care setting.
BACKGROUND: Circulating B-type natriuretic peptide (BNP) concentrations strongly predict mortality in patients with heart failure (HF). Both cardiac and extracardiac stimuli influence BNP levels, suggesting that BNP might have similar prognostic value in patients without HF. OBJECTIVES: The aim of this study was to compare the prognostic value of BNP between patients with and those without HF. METHODS: Using the Vanderbilt University Medical Center electronic health record, 30,487 patients (median age 63 years, 50% men, 17% black, 38% with HF) who had a first plasma BNP measurement between 2002 and 2013, with follow-up through 2015, were studied. The risk for death according to BNP level was quantified using multivariate Cox proportional hazards models. RESULTS:BNP levels were lower in patients without HF (median 89 pg/ml; interquartile range: 34 to 238 pg/ml) compared with those with HF (median 388 pg/ml; interquartile range: 150 to 940 pg/ml) (p < 0.0001). Over 90,898 person-years of follow-up, 5,903 patients without HF (31%) and 6,181 patients with HF (53%) died. In multivariate models including demographic and clinical characteristics, BNP and age were the strongest predictors of death in both patients with and those without HF. In acute care settings and even among outpatients with modestly elevated BNP, the risk for death according to BNP was similar between patients with and those without HF. For instance, a BNP level of 400 pg/ml was associated with a 3-year risk for death of 21% (95% confidence interval: 20% to 23%) and 19% (95% confidence interval: 17% to 20%) in patients with and those without HF, respectively. CONCLUSIONS: Among patients without HF, plasma BNP level is a stronger predictor of death than traditional risk factors. The risk for death associated with any given BNP level is similar between patients with and those without HF, particularly in the acute care setting.
Authors: Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos Journal: Circulation Date: 2005-10-04 Impact factor: 29.690
Authors: A S Maisel; J Koon; P Krishnaswamy; R Kazenegra; P Clopton; N Gardetto; R Morrisey; A Garcia; A Chiu; A De Maria Journal: Am Heart J Date: 2001-03 Impact factor: 4.749
Authors: Deepak K Gupta; Lori B Daniels; Susan Cheng; Christopher R deFilippi; Michael H Criqui; Alan S Maisel; Joao A Lima; Hossein Bahrami; Philip Greenland; Mary Cushman; Russell Tracy; David Siscovick; Alain G Bertoni; Valentina Cannone; John C Burnett; John Jeffrey Carr; Thomas J Wang Journal: Am J Cardiol Date: 2017-06-30 Impact factor: 2.778
Authors: J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald Journal: N Engl J Med Date: 2001-10-04 Impact factor: 91.245
Authors: K Yamamoto; J C Burnett; M Jougasaki; R A Nishimura; K R Bailey; Y Saito; K Nakao; M M Redfield Journal: Hypertension Date: 1996-12 Impact factor: 10.190
Authors: James L Januzzi; Rahul Sakhuja; Michelle O'donoghue; Aaron L Baggish; Saif Anwaruddin; Claudia U Chae; Renee Cameron; Daniel G Krauser; Roderick Tung; Carlos A Camargo; Donald M Lloyd-Jones Journal: Arch Intern Med Date: 2006-02-13
Authors: Bo K Lauridsen; Kasper Iversen; Ingrid Hunter; Morten Bay; Vibeke Kirk; Olav W Nielsen; Henrik Nielsen; Søren Boesgaard; Lars Køber; Jens P Goetze Journal: BMJ Open Date: 2013-11-25 Impact factor: 2.692
Authors: Nirav Patel; Mary Cushman; Orlando M Gutiérrez; George Howard; Monika M Safford; Paul Muntner; Raegan W Durant; Sumanth D Prabhu; Garima Arora; Emily B Levitan; Pankaj Arora Journal: JCI Insight Date: 2019-06-04
Authors: Hannah Fish-Trotter; Jane F Ferguson; Nirav Patel; Pankaj Arora; Norrina B Allen; Katherine N Bachmann; Lori B Daniels; Muredach P Reilly; Joao A C Lima; Thomas J Wang; Deepak K Gupta Journal: Circ Heart Fail Date: 2020-06-08 Impact factor: 8.790
Authors: John Gierula; Richard M Cubbon; Maria F Paton; Rowenna Byrom; Judith E Lowry; Sarah F Winsor; Melanie McGinlay; Emma Sunley; Emma Pickles; Lorraine C Kearney; Aaron Koshy; Thomas A Slater; Hemant K Chumun; Haqeel A Jamil; Kristian M Bailey; Julian H Barth; Mark T Kearney; Klaus K Witte Journal: Eur Heart J Qual Care Clin Outcomes Date: 2019-07-01